What development phase is DIMYRISTOYL LECITHIN in?

DIMYRISTOYL LECITHIN is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

DIMYRISTOYL LECITHIN

FDA-approved approved Quality 1/100

Dimyristoyl lecithin is a marketed drug with a key composition patent expiring in 2028. The drug's market position and specific mechanism of action are not detailed, but its patent protection provides a competitive advantage until expiry. The primary risk is the potential for increased competition post-2028, which could impact revenue.

At a glance

Generic name	DIMYRISTOYL LECITHIN
Phase	FDA-approved
First approval	2002

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DIMYRISTOYL LECITHIN CI brief — competitive landscape report
DIMYRISTOYL LECITHIN updates RSS · CI watch RSS